Clinical trial
The Efficacy and Safety of Azacitidine in Combination With Chidamide in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma Unfit for Conventional Chemotherapy
NCT04480125 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Azacitidine in Combination With Chidamide in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma Unfit for Conventional Chemotherapy
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 20, 2020
- Completion date
- June 20, 2024
- Enrollment
- 28 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
peripheral t-cell lymphoma